

NEWS RELEASE

NeuroVive Pharmaceutical AB (publ)
556595-6538

14 April, 2016



THIS DOCUMENT IS NOT TO BE DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE US, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE SUBJECT TO LEGAL RESTRICTIONS.

NeuroVive publishes prospectus and announces new publication date of the Q1 interim report

On 28 February 2016, the Board of Directors of NeuroVive Pharmaceutical AB (publ) ("NeuroVive") decided to carry out a new issue of shares and warrants (units) with preferential rights for the company's existing shareholders. In conjunction with this new issue, NeuroVive has published a prospectus today, which has been approved and registered by the Swedish Financial Supervisory Authority. The Board of Directors of NeuroVive has also decided to postpone the publication date of the Q1 interim report due to the forthcoming new issue.

Upon full subscription, NeuroVive would raise approximately SEK 94.4 million before issue expenses. Upon full utilization of the warrants, NeuroVive will raise a minimum of a further SEK 32.6 million before issue expenses. The new issue is guaranteed to 75 percent, or approximately SEK 70.9 million, through guarantee commitments.

Specific financial information that has not been previously disclosed

The prospectus includes specific financial information regarding equity, net indebtedness, and receivables as well as cash and cash equivalents as of 31 January 2016, which has not previously been published.

As of 31 January 2016, NeuroVive's equity was SEK 156,943,000. The company's cash and cash equivalents as of 31 January 2016 were SEK 91,958,000. The company's receivables were SEK 2,690,000. Accordingly, the company's net indebtedness was SEK -94,648,000 as of 31 January 2016. Comprehensive information on the company's equity, receivables and net indebtedness as of 31 January 2016, is on page 49 of the prospectus.

Prospectus

Prospectus, application forms and other relevant information are available at the company's premises and for download from the company's website www.neurovive.com/index.php/en/investors/shareholder-reports. The prospectus is also available at the Swedish Financial Supervisory Authority's website www.fi.se and at Aqrat Fondkommission AB's website www.aqrat.se. An information pack, pre-printed share issue documentation and covering letter will be sent to direct-registered shareholders. Nominee-registered shareholders will only receive information packs and covering letters. Printed prospectuses and application forms are available to order free of charge via e-mail; info@aqrat.se or by mail at Aqrat Fondkommission AB, 'NeuroVive', Box 7461, 103 92 Stockholm, Sweden.

Schedule for new issue

- The record date for rights to participation in the new issue was 8 April 2016

NEWS RELEASE

NeuroVive Pharmaceutical AB (publ)
556595-6538

14 April, 2016



- Subscription period: 18 April - 2 May 2016
- Trading in unit rights: 18 - 28 April 2016

Advisors

Stockholm Corporate Finance AB is acting as financial adviser and Advokatfirman Lindahl KB is acting as legal adviser in connection with the new issue. Aqurat Fondkommission AB will serve as issuing agent for the new issue.

New publication date of the Q1 interim report

The board of directors of NeuroVive has decided to postpone the publication date of the Q1 interim report from May 19 2016 to May 31 2016 due to preparation of the forthcoming rights issue.

About NeuroVive

NeuroVive Pharmaceutical AB (publ) is a pioneer in mitochondrial medicine and a company committed to the discovery and development of highly targeted candidates that preserve mitochondrial integrity and function in areas of significant therapeutic need. NeuroVive's business approach is driven by value-adding partnerships with mitochondrial research institutions and commercial partners across the globe. NeuroVive's portfolio consists of two clinical projects in acute kidney injury (AKI) and traumatic brain injury (TBI) with candidates in clinical and preclinical development and two drug discovery platforms. The NeuroSTAT® product has orphan drug status in Europe and in the US for treatment of moderate to severe traumatic brain injury and is currently being evaluated in a study, CHIC. Ciclosporin (CicloMulsion®) is being evaluated in an on-going study, CiPRICS, in acute kidney injury during major surgery. NeuroVive's shares are listed on Nasdaq, Stockholm, Sweden.

For investor relations and media questions, please contact:

Christine Tadgell, Tel: +46 (0)46 275 62 21 or ir@neurovive.com

NeuroVive Pharmaceutical AB (publ)

Medicon Village, SE-223 81 Lund, Sweden

Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48

info@neurovive.com, www.neurovive.com

NeuroVive Pharmaceutical AB (publ) is obligated to publish the information contained in this press release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication at 13:30 CET on 14 April 2016.

IMPORTANT INFORMATION

Publication or distribution of this press release in certain jurisdictions may be subject to restrictions according to law and the people in jurisdictions where this press release has been made public or distributed should inform themselves and follow such legal restrictions. This press release does not contain and does not constitute or form part of an invitation to acquire or subscribe or a solicitation of any offer to buy or subscribe for shares, warrants or other securities in NeuroVive. Any invitation

NEWS RELEASE

NeuroVive Pharmaceutical AB (publ)
556595-6538

14 April, 2016



to the persons concerned to subscribe for units in NeuroVive will only be made through the prospectus referred to in this press release.

This press release may not be published or distributed, directly or indirectly, in or into the US, Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or in any other jurisdiction where such distribution would be prohibited by applicable law. The information in this press release may not be redistributed, reproduced or passed on in ways that conflict with applicable restrictions. Failure to comply with these restrictions may constitute a violation of the United States Securities Act of 1933 or applicable laws of other jurisdictions.